Weekly Research Analysts’ Ratings Updates for TherapeuticsMD (TXMD)

A number of firms have modified their ratings and price targets on shares of TherapeuticsMD (NASDAQ: TXMD) recently:

• 1/8/2025 – TherapeuticsMD is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 1/2/2025 – TherapeuticsMD is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 12/27/2024 – TherapeuticsMD is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 12/21/2024 – TherapeuticsMD is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 12/15/2024 – TherapeuticsMD is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 12/9/2024 – TherapeuticsMD is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 12/3/2024 – TherapeuticsMD is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/27/2024 – TherapeuticsMD is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/21/2024 – TherapeuticsMD is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/15/2024 – TherapeuticsMD is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.

TherapeuticsMD Stock Down 1.9 %

TXMD traded down $0.02 during trading on Friday, hitting $1.09. The company’s stock had a trading volume of 23,906 shares, compared to its average volume of 2,677,189. The business’s fifty day simple moving average is $1.29 and its 200 day simple moving average is $1.56. TherapeuticsMD, Inc. has a twelve month low of $0.70 and a twelve month high of $2.75.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP grew its stake in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 636,622 shares of the company’s stock after purchasing an additional 101,282 shares during the period. Clearline Capital LP owned approximately 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 30.74% of the stock is owned by institutional investors.

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.